Compare VanEck Gold Miners ETF (GDX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs TransMedics Group Inc — how do they compare? VanEck Gold Miners ETF trades at $89.3 (market cap $25.65B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: VanEck Gold Miners ETF is far larger — about 9.4× TransMedics Group Inc's market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and TransMedics Group Inc for 24 Days on average.
| GDX | TMDX | |
|---|---|---|
Market Cap | $25.65B | $2.74B |
Volume | 16,534,046 | 949,331 |
52-Week High | $115.84 | $150.42 |
52-Week Low | $68.28 | $61.99 |
Typical Hold Time | 76 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.24, up 4.42% today but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with Allworth Financial and HB Wealth Management reducing positions while Ameritas Advisory Services increased its stake by 315.7%.
Gold miners offer leverage to gold prices but face volatility from interest rate sensitivity and operational risks. Current technical weakness suggests near-term pressure, though long-term fundamentals remain supported by gold's defensive characteristics amid macroeconomic uncertainty. The divergence between physical gold performance and miner valuations presents both risk and opportunity for investors.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
